Asahi Kasei Corporation AHKSY
20.00 USD -0.03 (-0.15%)
At closeNov 3, 2026, 4:00 PM EST
19.97 Day range 20.00
15.32 52-week range 24.12
- YTD
- +13.06%
- 1 year
- +30.46%
- Market cap
- 13.34B
- EPS (ttm)
- 1.84
- P/E ratio
- 10.87
- YTD return
- +13.06%
- 1-year return
- +30.46%
- Volume
- 108
- Avg volume
- 36.76K
- Open
- 19.99
- Previous close
- 20.03
- Day's range
- 19.97 – 20.00
- 52-week range
- 15.32 – 24.12
- Earnings date
- Nov 4, 2026
2Y +5.12 (+34.41%)
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.3972.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 0.3972 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | 0.3889 | 0.499 | +0.11 | +28.31% |
| May 8, 2026 | Mar 31, 2026 | 0.2718 | 0.3571 | +0.09 | +31.38% |
| Feb 4, 2026 | Dec 31, 2025 | 0.4378 | 0.48 | +0.04 | +9.64% |
| Nov 5, 2025 | Sep 30, 2025 | 0.4422 | 0.31 | -0.13 | -29.90% |
| Jul 31, 2025 | Jun 30, 2025 | 0.2741 | 0.45 | +0.18 | +64.17% |
News
Asahi Kasei (OTCMKTS:AHKSY) Stock Price Down 4.5% – Should You Sell? 
Asahi Kasei Corp. (OTCMKTS:AHKSY) Sees Large Increase in Short Interest 
Asahi Kasei Therapeutics Announces FDA Approval of HOVILPRI® (pritelivir) Tablets for Mucocutaneous HSV Lesions Refractory (With or Without Resistance) to Standard Antiviral Treatment in Immunocompromised Adults 
US FDA approves Asahi Kasei's drug for persistent herpes infections 
Asahi Kasei Microdevices Holds IEEE Milestone Commemoration Ceremony in Nobeoka for the Commercialization of Thin-Film Hall Elements 
Asahi Kasei Therapeutics Announces First Patient Dosed in Phase 2a Trial of AIC468 for BK Virus Infection in Kidney Transplant Recipients 
Asahi Kasei to Integrate Global Pharmaceutical Brand Under Asahi Kasei Therapeutics 
Asahi Kasei Introduces VANTIJ® SU-VFC Benchtop to Improve Efficiency and Consistency in Gene Therapy Manufacturing 
Asahi Kasei Unveils New Wet-Process Separator Coating Line in North Carolina, Advancing the Company's 40-Year North American Battery Separator Strategy 
Asahi Kasei Develops Novel Lithium Pre-doping Technology to Raise Energy Density and Lower Cost of Silicon-rich Lithium-ion Batteries
Your note
Sign in to keep a note on AHKSY — it syncs with the Stock Master app.